Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy

Tumors use Indoleamine 2,3-dioxygenase-1 (IDO1) as a major mechanism to induce an immunosuppressive microenvironment. IDO1 expression is upregulated in many cancers and considered to be a resistance mechanism to immune checkpoint therapies. IDO1 is induced in response to inflammatory stimuli such as...

Full description

Bibliographic Details
Main Authors:	Gomes, B, Driessens, G, Bartlett, D, Cai, D, Cauwenberghs, S, Crosignani, S, Dalvie, D, Denies, S, Dillon, C, Fantin, V, Guo, J, Letellier, M, Li, W, Maegley, K, Marillier, R, Miller, N, Pirson, R, Rabolli, V, Ray, C, Streiner, N, Torti, V, Tsaparikos, K, Van Den Eynde, B, Wythes, M, Yao, L, Zheng, X, Tumang, J, Kraus, M
Format:	Journal article
Language:	English
Published:	American Association for Cancer Research 2018

Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy

Similar Items